USPTO 2015–2025 USPTO PatentsView US Corporation

Sangamo Therapeutics, Inc.

USPTO PatentsView assignee record - 146 granted patents across 14 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

146

Total patents granted

CPC technology areas

12.3

Avg claims per patent

+35%

5-year filing velocity

The verdict

Sangamo holds 146 US patents across 14 technology areas, rank #2,670 of 50,000 tracked assignees.

#2,670
of 50,000 US assignees by volume: Top 32%
by Innovation Score (41.8/100): 12.3
avg claims per patent: +35%
filing velocity, last 5 yrs

Portfolio overview

Sangamo Therapeutics, Inc. has been granted 146 US utility patents between 2017 and 2025, placing Sangamo Therapeutics, Inc. at rank #2,670 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Sangamo Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Sangamo sits between Safran Transmission Systems (146 patents, rank #2,666) and Clark Equipment Company (145 patents, rank #2,674) - the closest US assignees by grant volume. The composite Innovation Score of 41.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 84 grants, compared with 62 in the 2015–2019 window, a +35% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sangamo Therapeutics, Inc.'s 12.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sangamo Therapeutics, Inc. against peers pursuing similar technology classes.

Safran Transmissi…

146
Shenzhen Royole

146
SPIN Memory

146
Samsonite IP Hold…

146
Scienbizip Consul…

146
Sangamo Therapeut… ◀

146
Abbott Point of C…

145
Analogic

145
Clark Equipment

145

What this shows Sangamo holds 146 patents at rank #2,670, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sangamo

By rank, the assignees closest to #2,670 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Sangamo's primary technology class.

Sangamo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Sangamo Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	13	8.9%
2018	26	17.8%
2019	23	15.8%
2020	24	16.4%
2021	20	13.7%
2022	14	9.6%
2023	18	12.3%
2024	7	4.8%
2025	1	0.7%

Which technologies does Sangamo Therapeutics, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 143

C07K - PEPTIDES 108

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 86

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 85

C12Y - ENZYMES 43

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 14

A01H - NEW PLANTS OR ; NON-TRANSGENIC; PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES 7

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 6

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 5

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

B01D - SEPARATION 1

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 1

C40B - COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES 1

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 1

Top 14 of 14 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#2,670

Across all tracked assignees

Innovation Score

41.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sangamo Therapeutics, Inc. hold?

Sangamo Therapeutics, Inc. holds 146 US granted patents filed between 2017 and 2025, spanning 14 technology areas.

What is Sangamo Therapeutics, Inc.'s Innovation Score?

Sangamo Therapeutics, Inc. has an Innovation Score of 41.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sangamo Therapeutics, Inc. focus on?

Sangamo Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 143 patents. The company has filed patents in 14 CPC subclasses total.

Is Sangamo Therapeutics, Inc.'s patent filing rate increasing or decreasing?

Sangamo Therapeutics, Inc.'s recent filing velocity is +35% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Sangamo Therapeutics, Inc.'s patents?

Sangamo Therapeutics, Inc.'s patents average 12.3 claims each. This falls within the standard range, providing solid legal coverage.

How is the Sangamo Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Sangamo's 146 grants land it in the top 32% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Sangamo ranks #2,670 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.